Eli Lilly and Company is investing another $4.5 billion into its Indiana operations as the drugmaker expands production of obesity treatments and advanced genetic medicines. The latest announcement brings Eli Lilly’s Indiana manufacturing expansion to more than $21 billion in commitments across the state since 2020.
The company also opened the first phase of Lebanon Advanced Therapies, a new genetic medicine manufacturing facility designed to support both clinical research and large-scale commercial production.
The announcement comes as pharmaceutical companies race to expand domestic pharmaceutical manufacturing in the United States for obesity medicines, diabetes treatments, and advanced therapies amid rising global demand.
According to the company, the investment will support future production of Foundayo, Lilly’s newly approved once-daily obesity pill, and retatrutide, an investigational treatment currently in late-stage development.
What Is Lilly’s New Lebanon Medicine Facility?
The new advanced therapies facility by Eli Lilly is located in Lebanon and represents Lilly’s first dedicated genetic medicine facility.
The site is designed to manufacture therapies that target diseases at the genetic level. These medicines often work by modifying or replacing faulty genetic instructions inside cells. Lilly said the facility will support the full development process, from early research-stage medicines to large-scale commercial supply.
The site is the first of three planned facilities on Lilly’s Lebanon campus. Future projects include the Lilly Lebanon API site and the Lilly Medicine Foundry.
In a company statement, CEO David A. Ricks said the company is investing in “the medicines of the future” while building advanced manufacturing capacity in the United States.
Obesity Drug Production Drives New Investment
A major focus of Eli Lilly’s new Indiana medicine facility is the production of obesity drugs. Demand for weight-loss treatments has surged globally as newer medicines show significant results for patients living with obesity and type 2 diabetes.
Lilly previously announced plans to manufacture injectable obesity medicines, including Zepbound and Mounjaro, at its Lebanon API facility. The latest medicine manufacturing investment by Eli Lilly expands those plans further.
The company confirmed the expanded site will also support production of Foundayo oral weight loss pill, known scientifically as orforglipron. Unlike injectable GLP-1 treatments, Foundayo is a once-daily pill that can be taken without food or water restrictions.
Lilly is also preparing for potential future production of retatrutide, a next-generation obesity treatment currently being studied in Phase 3 clinical trials.
The demand for obesity medications is reshaping pharmaceutical manufacturing worldwide. Drugmakers are increasing production capacity as more countries approve new weight-management therapies.
Economic Impact on Indiana As a Production Facility
Indiana leaders say the investment further strengthens the state’s growing life sciences sector.
Governor Mike Braun said, “The expansion would create jobs and reinforce Indiana’s role in pharmaceutical innovation and advanced manufacturing.”
Lilly accounts for roughly 70% of Indiana’s pharmaceutical GDP, and each Lilly job supports more than two additional jobs across the state economy.
The Lebanon campus is part of Indiana’s LEAP District, a large industrial development project aimed at attracting advanced manufacturing and technology companies.
However, rapid industrial growth can raise concerns about infrastructure needs, particularly for water and energy usage in Boone County.
Lilly’s Domestic Medicine Manufacturing Strategy
Major pharmaceutical companies are increasing US-based manufacturing investments amid supply chain concerns and potential tariff pressures.
Lilly’s U.S. capital expansion commitments have now surpassed $50 billion since 2020. The company plans to break ground on additional manufacturing projects later this year.
Domestic weight drug manufacturing has become increasingly important as obesity medicines emerge as one of the fastest-growing sectors in healthcare. Eli Lilly’s Indiana manufacturing expansion aims to improve long-term medicine supply while supporting research into next-generation obesity and genetic treatments.
As demand for advanced therapies continues to grow, Lilly’s new facilities in Lebanon, Indiana, could play an increasingly important role in shaping the next generation of medicine.
